Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

ClinicalTrials.gov ID: NCT00524368

Public ClinicalTrials.gov record NCT00524368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 20, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-label Trial to Compare the Efficacy, Safety and Tolerability of DRV/Rtv (800mg/100mg) q.d Versus DRV/Rtv (600mg/100mg) b.i.d in Early Treatment-experienced HIV-1 Infected Subjects

Study identification

NCT ID
NCT00524368
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Enrollment
590 participants

Conditions and interventions

Interventions

  • Darunavir (DRV) Drug
  • Ritonavir (rtv) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2007
Primary completion
Jul 31, 2009
Completion
Sep 30, 2011
Last update posted
Feb 14, 2013

2007 – 2011

United States locations

U.S. sites
30
U.S. states
14
U.S. cities
30
Facility City State ZIP Site status
Not listed Phoenix Arizona
Not listed Little Rock Arkansas
Not listed Beverly Hills California
Not listed Oakland California
Not listed Palm Springs California
Not listed Fort Lauderdale Florida
Not listed Fort Laudersale Florida
Not listed Miami Florida
Not listed Miami Beach Florida
Not listed Orlando Florida
Not listed Safety Harbor Florida
Not listed West Palm Beach Florida
Not listed Atlanta Georgia
Not listed Macon Georgia
Not listed Savannah Georgia
Not listed Chicago Illinois
Not listed Springfield Massachusetts
Not listed Berkley Michigan
Not listed Newark New Jersey
Not listed Albany New York
Not listed New York New York
Not listed Rochester New York
Not listed The Bronx New York
Not listed Huntersville North Carolina
Not listed Winston-Salem North Carolina
Not listed Akron Ohio
Not listed Charleston South Carolina
Not listed Dallas Texas
Not listed Harlingen Texas
Not listed Houston Texas

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00524368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 14, 2013 · Synced Jul 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00524368 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →